UNITY Biotechnology

2023 was a pivotal year for UNITY.     As we turn the page to 2024, we’re looking forward to continuing our mission to redefine the treatment paradigm for #DME. With many upcoming milestones, we’re thrilled to continue our momentum into the new year. Stay tuned for more to come!     #UBX1325 #JPM24 #ReimagineAging 

As we near the end of the year, we reflect on the progress we’ve made to bring senolytic therapies to patients with serious retinal diseases.    Thank you to our team, partners, investigators, our patient community, and all who continue to support our efforts to develop potentially transformative therapies to address the underlying biology of chronic and inflammatory diseases.    Wishing you happy holidays ahead! 

Senescent cells rely on the BCL-xL protein for survival. By inhibiting BCL-xL in the retina, diseased senescent cells are eliminated while leaving healthy blood vessels intact.   Our senolytic candidate #UBX1325 is designed to target BCL-xL, selectively removing a source of pathogenesis to restore vasculature to a healthier state and potentially lead to long-term disease modification for #DME.   Discover our #senolytic approach: https://bit.ly/4fMKjXp 

1.7 million people live with diabetic macular edema (#DME) in the U.S., and about 700,000 are diagnosed and treated. With nearly a third of patients affected in both eyes, the demand for effective treatments to slow and reverse disease progression is more urgent than ever.     With #UBX1325, we aim to address this unmet need by offering a novel approach that may improve long-term visual outcomes for patients.     Hear more about our efforts to bring our senolytic candidate to patients from our CSO Alicia Tozier below.     Discover our scientific approach: https://bit.ly/4fMKjXp  

Join our Chief Scientist Mike (Przemyslaw) Sapieha, Ph.D. at the Longevity Global 2024 Longevity Summit this week!    Onsite at the Buck Institute for Research on Aging, speakers will gather to discuss this year’s theme “The Future of Medicine: Eliminating Diseases of Aging.”   Register here: https://lnkd.in/gx8Q8mYT

UBX1325 targets BCL-xL, a protein essential for the survival of senescent cells in the retina. This #senolytic approach is designed to remove senescent cells and consequently heal retinal tissues, possibly improving retinal function and restoring vision for #DME patients.     Read more from Kathy Liszewski in Genetic Engineering & Biotechnology News: https://bit.ly/4dVBo4n     #ophthalmology #retina #UBX1325 Anirvan Ghosh

November is both #AmericanDiabetesMonth and #DiabeticEyeDiseaseMonth. As specialists, remind your community about the importance of regular eye exams to prevent vision loss in individuals with diabetes. Share helpful eye health resources: https://lnkd.in/dvmVsaZ2 #EyeHealth Genentech

November is Diabetic Eye Disease Awareness Month, a time to bring attention to the silent but serious impacts of diabetes on vision.   Diabetic eye diseases like diabetic macular edema (#DME) affect hundreds of thousands of adults in the US, often leading to vision loss that can disrupt day-to-day life and cherished moments with family and friends.   Together with the patient community, we’re striving to make a brighter future a reality for those affected by diabetic eye disease.

This week, we announced our Q3 2024 financial results and business updates on our senolytic program evaluating #UBX1325 in diabetic macular edema (#DME). Read the full release: https://bit.ly/4hAkVWu

In Genetic Engineering & Biotechnology News’ recent article, CEO Anirvan Ghosh, Ph.D. explains how targeting the BCL-xL protein in senescent cells can potentially reverse DME disease progression, constituting the basis of our senolytic approach.   Learn more about #UBX1325’s mechanism of action: https://bit.ly/4dVBo4n